Provectus Biopharmaceuticals Inc - PVCT stock

From OTC Wiki

OTC Symbol: PVCT | OTC Tier: OTCQB

Introduction[edit]

Provectus Biopharmaceutical Inc is a clinical-stage biotechnology company that is primarily involved in the development and research of immunotherapy medicines. These medicines are built using small molecules called halogenated xanthenes, the entire class of which is owned by Provectus Biopharmaceuticals. The company has several drugs and research studies under pipeline that are aimed at treating diseases in various areas such as oncology, dermatology, hematology, virology, microbiology, and ophthalmology. [1] The company was founded in 2002 and is based on the United States.[2]

Product Development[edit]

The company is primarily involved in developing immunotherapy medicines for different diseases, based on a family of small molecules called halogenated xanthenes (“HXs”). The lead molecule used by Provectus Biopharmaceuticals is named rose bengal sodium (“RBS”). The company holds a number of patents for research which have been completed and continues further research for the production of investigational drugs and other technologies. [3]

The company's primary compound is rose bengal sodium (RBS). Its clinical development initiatives encompass PV-10 for addressing stage III and IV melanoma, various liver cancers, and PH-10 for managing psoriasis and atopic dermatitis. Furthermore, it includes PV-305 for treating infectious keratitis. The company is also working on oral formulations for treating solid tumor cancers in adults, as well as refractory and relapsed pediatric cancers, including leukemias. Additionally, it is developing PV-10 for managing relapsed and refractory pediatric solid tumor cancers, alongside other formulations targeting cutaneous canine cancers and the healing of full-thickness cutaneous wounds. Moreover, it is engaged in the development of oral and intranasal formulations for managing severe acute respiratory syndrome coronavirus 2, bacterial infections (both gram-positive and gram-negative), oral bacterial infections, fungal infections, vertebrate development, wound healing, and tissue regeneration.[2]

On Nov 10 2022, announced that data from the Company’s ongoing, multi-cohort, Phase 1b/2 study of the combination therapy of cancer immunotherapy PV-10, a formulation of Provectus’ small molecule rose bengal sodium (RBS), and immune checkpoint inhibitor KEYTRUDA® (pembrolizumab) for the treatment of Stage III cutaneous melanoma would be presented at Melanoma Bridge 2022, which will take place in Naples, Italy and online from December. [4]

Collaboration[edit]

Bascom Palmer Eye Institute and University of Miami[edit]

The Company holds an option agreement with the University of Miami (UM) for an exclusive global license of intellectual property created by the Ophthalmic Biophysics Center of Bascom Palmer Eye Institute, a component of the UM Health System. This license pertains to the utilization of OBC’s photodynamic antimicrobial therapy medical device alongside Provectus’ proprietary pharmaceutical-grade rose bengal, specifically for addressing bacterial, fungal, and viral infections of the eye. Additionally, the Company has launched a sponsored research program with OBC to explore the potential of Provectus’ rose bengal in treating infectious keratitis.[5]

Management Team[edit]

The leadership and management team at Provectus Biopharmaceuticals is highly experienced with expertise in their respective domains. The leadership team consists of Bruce Horowitz (CEO), Eric Wachter (CTO), and Heather Raines (CFO).[6]

Mr Horowitz has been the company’s CEO since 2019, prior to which he was the Chief Operations Consultant from 2017 to 2019. He is highly experienced in the capital markets with prior experience in Capital Strategists, Drake Capital Securities, and Stanley Capital. Dr Wachter has been a part of the company since 2012 and holds a PhD in Chemistry from the University of Wisconsin–Madison. Heather Raines is a CPA-Certified Accountant and has been associated with the company since 2017.[6]

Provectus also has a team of a strategic and scientific advisory board that includes John Lacey III, Frank H. Akers, Harold Schmitz, and Aru Narendran. All of the members of the advisory board hold PhD in the medical field along with a vast experience in the medical industry that is helpful to Provectus Biopharmaceuticals in their research.[6]


The page is authored by: Wisdom Tree, Caesar